Researchers said Sunday that they have identified two drugs which could aid breathing and prolong life for patients suffering from an incurable lung disease.
The drugs, pirfenidone and nintedanib, slow the decline of patients with idiopathic pulmonary fibrosis, the researchers said during a meeting of the American Thoracic Society in San Diego. Their findings were published in The New England Journal of Medicine. Although the drugs do not cure the disease, which scars and thickens the lungs making it hard to breathe, researchers called the findings a “major breakthrough” for an ailment that until now has had no treatment at all.
“I suspect that many of my patients have picked up on more than a hint of frustration in my voice when I tell them that the cause of their shortness of breath is idiopathic pulmonary fibrosis,” Dr. Gary M. Hunninghake, a lung specialist at Brigham and Women’s Hospital in Boston, wrote in an editorial accompanying the study. “This frustration stems from the fact that beyond providing information about prognosis or referral for lung transplantation or palliation, there has been little to offer in the way of treatment. …The game has now changed.”
The drugs’ manufacturers helped pay for the study, the New York Times reports. At least 80,000 Americans suffer from idiopathic pulmonary fibrosis, which causes scarring of the lungs and is fatal within three to five years for most patients.
More Must-Reads from TIME
- Why Trump’s Message Worked on Latino Men
- What Trump’s Win Could Mean for Housing
- The 100 Must-Read Books of 2024
- Sleep Doctors Share the 1 Tip That’s Changed Their Lives
- Column: Let’s Bring Back Romance
- What It’s Like to Have Long COVID As a Kid
- FX’s Say Nothing Is the Must-Watch Political Thriller of 2024
- Merle Bombardieri Is Helping People Make the Baby Decision
Contact us at letters@time.com